SEC Filing Summary: Point Capital, Inc. (10-K)
Business Context and Reporting Period
Company: Point Capital, Inc. (Note: Input metadata referenced "Silo Pharma," but the filing text identifies the registrant as Point Capital, Inc.)
Reporting Period: Fiscal year ended December 31, 2016.
Business Model: A closed-end, non-diversified Business Development Company (BDC) regulated under the Investment Company Act of 1940. The company invests in common stock, preferred stock, warrants, and convertible notes of small and mid-cap U.S. companies. It is taxed as a Regulated Investment Company (RIC).
Operations: The company has no full-time employees; executive officers provide services on a part-time basis. As of December 31, 2016, the portfolio consisted of 19 non-controlled, non-affiliated investments.
Key Financial Metrics
| Metric | 2016 | 2015 | 2014 |
|---|---|---|---|
| Total Investment Income | $49,836 | $47,141 | $20,565 |
| Total Operating Expenses | $443,494 | $264,313 | $269,435 |
| Net Investment Loss | $(393,658) | $(217,172) | $(248,870) |
| Net Realized Loss on Investments | $(402,764) | $(200,468) | $92,277 |
| Net Unrealized Depreciation | $(316,552) | $8,142 | $(219,956) |
| Net Decrease in Net Assets from Operations | $(1,112,974) | $(409,498) | $(376,549) |
| Cash and Cash Equivalents | $579,209 | $722,764 | $1,739,520 |
| Total Assets | $1,299,604 | $2,450,236 | N/A |
| Net Assets | $846,506 | $1,959,480 | N/A |
| Net Asset Value (NAV) per Share | $0.02 | $0.04 | $0.05 |
Liquidity: The company reported a decrease in cash of $143,555 in 2016, primarily used to pay professional fees and compensation. Management believes existing cash is sufficient for at least 12 months of operations.
Material Changes vs. Prior Period
- Portfolio Valuation: Investments at fair value dropped significantly from $1,691,518 in 2015 to $634,873 in 2016. This was driven by a net unrealized depreciation of $316,552 and net realized losses of $402,764.
- Realized Losses: Major realized losses in 2016 included sales of Pulmatrix, Inc. (~$236,200), Actinium Pharmaceuticals Inc. (~$88,000), PhaseRX, Inc. ($42,800), and Orbital Tracking Corp. ($34,200). Additionally, the investment in MultiMedia Platforms, Inc. was written down to zero following its Chapter 11 bankruptcy filing.
- Operating Expenses: Total operating expenses increased by 67.8% to $443,494 in 2016 compared to 2015. This was primarily due to a 147.6% increase in professional fees (driven by audit and legal fees related to Investment Act matters) and a 47.5% increase in compensation expenses.
- NAV Decline: Net Asset Value per share decreased by 50% from $0.04 in 2015 to $0.02 in 2016.
Guidance, Risks, and Contingencies
- Internal Control Weaknesses: Management identified material weaknesses in internal controls over financial reporting. Specific deficiencies included failure to timely recognize that shares issued to a consultant in 2014 and stock options to directors in 2015 were in contravention of the Investment Company Act of 1940, lack of segregation of duties, and lack of control over investment valuations.
- SEC Examination: The company was under examination by the SEC regarding compliance with federal securities laws. While the company believed findings were resolved, it was preparing a written response as of the filing date.
- Regulatory Risks: As a BDC, the company must maintain 70% of assets in "qualifying assets" and maintain an asset coverage ratio of at least 200% if issuing senior securities. Failure to maintain RIC status would subject the company to corporate-level income taxes.
- Liquidity Risk: The company has no agreements to raise capital. If additional funds are needed to invest or operate, they may not be available on acceptable terms, potentially forcing a reduction in investment activities or cessation of operations.
- Portfolio Concentration: Approximately 78% of the portfolio fair value consisted of securities not publicly traded, creating valuation uncertainty and liquidity constraints.
Key Facts for Investor Verification
- Material Weaknesses: Verify the status of remediation plans for the identified internal control failures, specifically regarding the unauthorized issuance of equity in 2014 and 2015.
- Portfolio Valuation: Review the fair value determinations for Level 3 assets (private securities), which comprised the majority of the portfolio and were subject to significant write-downs.
- SEC Compliance: Confirm the final resolution of the SEC examination and any potential penalties or required restatements.
- Cash Runway: Assess the sufficiency of the $579,209 cash balance against the high operating expense ratio (30.04% of average net assets) to determine the timeline for potential capital raises.
- Preferred Stock: Note the existence of $400,000 in Series A Convertible Preferred Stock, which has liquidation preference and specific voting rights that could impact common shareholders.